

MEDICAID DRUG REBATE PROGRAM

Release Number 61

* * * IMMEDIATE ATTENTION REQUIRED * * *

NOTE TO: All State Medicaid Directors

BANKRUPTCY FILINGS BY DRUG LABELERS

Region VI received notification that Vanguard Labs, (Labeler Code 00615), and Syosset Laboratories, Inc. (Labeler Code 47854), filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code, in the Bankruptcy Court. It is important that States protect their interest (and the Federal Government's interest) in the rebates that are owed.

States are expected to file a proof of claim for their drug rebates in any bankruptcy proceeding of a drug manufacturer from whom a drug rebate is owed. Generally, a State would have six months under Chapter 11 USC 502(b)(9) to file a proof of claim for pre-petition obligations from the date the petition for bankruptcy is filed. Attorneys representing State Agencies should be able to protect their interest in such matters, once the State's obligation to file a claim is made clear. The post-petition rebate claims could also be affected by the bankruptcy proceedings. Therefore, States should take steps to assure such rebates are properly pursued.

ALSCRIPS

A repackager named ALSCRIPS (Labeler Code 54569), apparently does not wish to be an active participant in the rebate program. They do, however want their products covered by Medicaid. ALSCRIPS has included their NDC number AND the NDC number from the company they purchased products from on the package. They are telling physicians to bill Medicaid using the "other" NDC number. Drug products marketed by the ALSCRIPS company using the ALSCRIPS label are not eligible for Federal financial participation (FFP), and State pharmacies should be alerted to this illegal practice.

We have notified both the Food and Drug Administration and the Office of the Inspector General, and requested that they investigate this matter.

HCFA HOME PAGE ON THE INTERNET

Effective July 12, the following drug rebate data are available from the HCFA home page via INTERNET at <http://www.hcfa.gov>: all memoranda to State Medicaid Directors, all memoranda to participating drug labelers, the Consumer Price Index - Urban (CPI-U) values, the 91-day Treasury bill (T-bill) rates to two decimal positions, all State drug utilization for 1991 - 1995, all drug product baseline data (except for prices), drug labeler contact information for all participating drug companies, and a copy of the national drug rebate agreement.

Within 30 days, we plan to add the interest calculation methodology, the formula for calculating unit rebate amounts, a current listing of drugs subject to the federal upper limit (FUL), and the current quarterly listing of less-than-effective (LTE)/identical, related or similar (IRS) drugs as determined by the Food and Drug Administration. Comments and suggestions on the home page should be referred to Al Beachley at (410) 786-3276 or abeachley@hcfa.gov.

STATE REPORTING OF UNMATCHED NDC NUMBERS WITH HCFA DATA BASE

It has come to our attention that there are still manufacturers' NDC numbers that have not been reported to HCFA. The National Rebate Agreement requires manufacturers to report all their NDC numbers to HCFA. One State has reported unmatched NDC(s) on their State tape for Ortho (Labeler Code 59676). Ortho has been contacted and will be sending HCFA their unreported NDC(s). Any unmatched NDC numbers from Johnson & Johnson (Ortho, McNeil, OrthoBioTech & Janssen) or any other participating manufacturer should first be reported to the company involved to ascertain that this is a valid NDC number for the company. If the number is valid, HCFA should be alerted so that contact can be made with the company to get the information. HCFA should be contacted if further assistance is needed.

DRUG CATEGORY CHANGE

A situation regarding Drug category changes has caused us to change the way we recalculate prior quarter URAs for one specific situation only. If a repackager using their own NDC on a repackaged product begins buying from a company that will cause the Drug Category to change from or to "N", URAs back to the start of the product history will NOT be recalculated and will NOT cause PPA records to be generated. The Unit Rebates will only be recalculated for those quarters (if necessary), subsequent to the change in purchasing company. If you have any questions, please call Vince Powell on (410) 786-3314.

USING UPPS FIELD FOR CALCULATING UTILIZATION

We have, again, received a call from a drug company complaining that some States are NOT using their Units Per Package Size (UPPS) field when calculating total utilization for unbreakable packages. These States instead are using the UPPS (or its equivalent field) from the Medispan or First Databank file. Please remember that when calculating utilization for unbreakable packages, multiply the number of scripts times the UPPS field FROM THE HCFA TAPE to determine total utilization. DO NOT use this information from any other source. The HCFA file has the Units defined by the drug company which correspond to the way the company calculates units in order to develop their Average Manufacturer's Price (AMP). Regardless of whether the other files contain a UPPS field that matches NCPDP standards on rounding or unit values that are used for developing AWP, etc., the only accurate fields FOR THE DRUG REBATE PROGRAM FILES are those sent by HCFA.

NEW LABELER

The following labeler has entered into a drug rebate agreement and will join the rebate program on October 1, 1996:

P.L. Development, Inc. (Labeler Code 59726).

LABELER TERMINATIONS

The following labelers are being terminated effective October 1, 1996 for failure to submit pricing data:

ConvaTec (Labeler Code 00519),

Beiersdorf, Incorporated (Labeler Code 10356),

Ion Laboratories, Incorporated (Labeler Code 55532),

Dawn Pharmaceuticals (Labeler Code 58865),

CooperVision Pharmaceuticals, Incorporated (Labeler Code 59426),
and

Amkas Laboratories, Incorporated (Labeler Code 61073).

Colorplast Corporation (Labeler Code 62123) has withdrawn their Drug Rebate Agreement. Since they only manufacture medical devices, they were not eligible to participate in the program.

Delmont Laboratories, Incorporated (Labeler Code 48532) and Pharmed Group (Labeler Code 54252) have requested to be terminated from the program effective October 1, 1996.

ATTACHMENTS

Copies of the topic index and the latest listing of the 90-day treasury bill auction rates for the period of September 5, 1995 through July 22, 1996 are attached.

Please remember to direct your drug rebate questions to a staff member on the listing we provided with release number 53.

Sally K. Richardson
Director
Medicaid Bureau

2 Attachments

cc:

All State Technical Contacts
All Regional Administrators
All Associate Regional Administrators, Division of Medicaid

TOPICAL INDEX - STATE MEDICAID RELEASES 1 - 61

TOPIC	RELEASE #
1A Drug Listing	11
Additional Copies of Releases to SMDs	40
Adjustment Code for Forms HCFA-304 & HCFA-304a	57
Bankruptcy - Drug Labelers	19-61
Best Price to DSH Covered Entities	36
Betaseron - Coverage & Reimbursement	38-40
Bulk Transfer/Buy-Out of Major Pharm. Assets	54-55
Caverject Coverage	55
Closure During Federal Furloughs	57
Confidential Information Release	17
Constant Disputes by Drug Labelers	23
CPIU Information	09
Dataset Name Changes on Quarterly Rebate Tapes	41
Dipyridamole Issue	26
Dispute Resolution	
Definition	19
Issues	55
Process Stages	45
Workgroup Survey Results	42
Dispute Settlements	59
Drug Category Change	61
Drug Efficacy Study & Implementation (DESI)	
Change Effective Date	20
Change Schedule	18
Effective Date Revisions	23-24
Duplicate Discount/Rebate Mechanism Implementation	33
Enteral Nutritional Products - Coverage	30
Enteral Products	19
Experimental Drugs - Coverage	43
Hotline	53
Index for Drug Rebate Notes	31
Information Sharing	57
Interest Calculation under Section V(b)	29
Internet Home Page	61
Invoices	
Correct Labeler Address	36
Format	03
Incomplete Drug Labeler Data	18
Incorrect Invoicing	26
Remittance Advice Report Survey	35
Submission	19
Submitting for Multiple Quarters	36
Submitting to Drug Labelers	28
Labeler Contact File Changes	32
Late Submission of Quarterly Prices	33
LTE/IRS Drugs	26
Magnetic Media	
New Address for Shipping (Effective 6/1/95)	52
Rejections	15
Shipments	15-23
Specification Revision	14

TOPIC	RELEASE #
Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	27
Medical Supplies & Devices	03-16-26
Metric Conversion/Rounding	18
New Drug Products	41
New Rebate Agreement Status	23
OBRA '93	40
Overpayments Due to AMP Recalculations	57
PHS Drug Pricing Program	44
Prior Period Adjustments (PPAs)	60
Prior Period Adjustments - Eli Lilly & Company	37
Prior Authorization	55
Prior Period Adjustments	14-16
Prior Quarter Adjustment Statement (PQAS) Approval	60
Proposed Discount Equal Access Legislation	51
Publication of Drug Rebate Regulations MB-46-P	55
Quarterly Labeler Contact File	26
Quarterly Reporting - Form HCFA-64, 9r	40
Quarterly Tape Submission to HCFA	60
Quarterly Update File	14
Rebates	
Calculation Formula	07
Less than Administrative Costs	40
Partial Payments	55
Remittance/Check Address	30
Reconciliation of State Invoice (ROSI) Approval	60
Rejection of State Records Matching LTE Drugs	41
Remittance Advice Report/Workgroup	48-52-53-56
Reporting Utilization Changes to Labelers	57
Rescission of Termination for Novopharm USA	39
Separate Rebate Agreements with Manufacturers	38
Special Advisory Group	16
Staff Listing	53
Staff Relocation	52
Standard Summary Record Format	13
State Application of the FUL Program	48
State Contact Information	23-26-41
State Coverage	
LTE & IRS Drugs	40
Unit-Dose Drugs	19
State Data Validation Edits	33
State Hearing Process	44
State Invoices Containing Universal Product Codes	51
State Plan Amendment Requirement	47
State Responsibility - Terminated Drugs	19
State Utilization Data Records - Corrections	51
State Utilization Data Study (SUDS)	33
State Utilization Tape Submission Procedures	58
Tape/Cartridge Return Policy	19
Tape Submission Checklist	30
Terminated/Deleted Records	44

Termination From Program	55
TOPIC	RELEASE #
Timely Receipt of Tapes/Notices of Mailing	45
Tolerance Threshold Clarification	
For Interest	48
Rebate Amount Adjustments	44
Unit-Dose Packaging	15
Unit Per Package Size	03
Unit Rebate Amount (URA)	
Edits	43
Erroneous Amounts	51
Invoice when the Amount is Zero	44
Unit Type	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Revisions	32
UPPS Less Than 1.0	19
UPPS Used for Calculating Utilization	61
Use of Information from Outside Sources	48
Utilization Data	
Corrections/Problems	18
Late Submission	18
Receipt	29-31
Record Format	08-13
Set Naming Requirements	19
Tapes	40
Transmitting Corrections/Adjustments to HCFA	16-40
Vaccine	
Deletions	26
Exclusions	19-23
Policy Clarification	25

(Revised 24 July 1996)

WEEKLY U.S. T-BILL DISCOUNT RATE

The latest weekly 90-day treasury bill auction rates for September 5, 1995 through July 22, 1996 are:

DATE OF AUCTION	TRUE DISCOUNT RATE
09/05/95	5.463
09/12/95	5.504
09/19/95	5.409
09/25/95	5.293
10/02/95	5.504
10/10/95	5.471
10/16/95	5.483
10/23/95	5.376
10/30/95	5.450
11/06/95	5.525
11/13/95	5.599
11/20/95	5.503
11/27/95	5.483
12/04/95	5.450
12/11/95	5.463
12/18/95	5.306
12/26/95	5.054
01/02/96	5.190
01/09/96	5.178
01/16/96	5.170
01/22/96	5.137
01/29/96	5.157
02/05/96	5.025
02/12/96	4.939
02/20/96	4.918
02/26/96	4.987
03/04/96	5.020
03/11/96	5.081
03/18/96	5.155
03/25/96	5.123
04/01/96	5.209
04/08/96	5.164
04/15/96	4.999
04/22/96	5.102
04/30/96	5.135
05/06/96	5.155
05/13/96	5.155
05/20/96	5.164
05/28/96	5.164
06/03/96	5.229
06/10/96	5.299
06/17/96	5.217
06/24/96	5.238
07/01/96	5.258
07/08/96	5.353
07/15/96	5.332
07/22/96	5.279

FAB134:Dmccarthy, 62079.
State61.WP